Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-524974-41-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-524974-41-00
Registry
EU Clinical Trials Information System
CTIS number
2025-524974-41-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic exploratory (Phase II)
Indication
Irritable Bowel Syndrome - Constipation
Status
Authorised
Start date
12/08/2026
Primary completion
CTIS does not publish one.
Member states concerned
Belgium, Spain
Sites
18

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-08-31

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded: mscPublicStatusCode takes values [2, 3] on this record and the registry publishes no key for them, so decoding it would be a guess.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2025-524974-41-00 in their own text.